- Home
- GES vs AUTL Comparison
GES vs AUTL Comparison
Compare GES & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GES
- AUTL
- Stock Information
- Founded
- GES 1981
- AUTL 2014
- Country
- GES Switzerland
- AUTL United Kingdom
- Employees
- GES N/A
- AUTL N/A
- Industry
- GES Apparel
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GES Consumer Discretionary
- AUTL Health Care
- Exchange
- GES Nasdaq
- AUTL Nasdaq
- Market Cap
- GES 547.7M
- AUTL 625.4M
- IPO Year
- GES 1996
- AUTL 2018
- Fundamental
- Price
- GES $11.92
- AUTL $2.31
- Analyst Decision
- GES Buy
- AUTL Strong Buy
- Analyst Count
- GES 4
- AUTL 5
- Target Price
- GES $17.75
- AUTL $9.32
- AVG Volume (30 Days)
- GES 968.1K
- AUTL 2.4M
- Earning Date
- GES 06-05-2025
- AUTL 08-07-2025
- Dividend Yield
- GES 10.07%
- AUTL N/A
- EPS Growth
- GES N/A
- AUTL N/A
- EPS
- GES 0.10
- AUTL N/A
- Revenue
- GES $3,051,131,000.00
- AUTL $9,011,000.00
- Revenue This Year
- GES $7.34
- AUTL $461.76
- Revenue Next Year
- GES $3.20
- AUTL $112.66
- P/E Ratio
- GES $123.29
- AUTL N/A
- Revenue Growth
- GES 9.02
- AUTL N/A
- 52 Week Low
- GES $8.48
- AUTL $1.11
- 52 Week High
- GES $24.64
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- GES 53.52
- AUTL 69.32
- Support Level
- GES $11.81
- AUTL $1.98
- Resistance Level
- GES $12.16
- AUTL $2.10
- Average True Range (ATR)
- GES 0.53
- AUTL 0.13
- MACD
- GES 0.00
- AUTL -0.00
- Stochastic Oscillator
- GES 54.27
- AUTL 73.63
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.